Q-omics provides the consensus-scored GAPDHP34 profile across patient tissues and cancer cell-line models. GAPDHP34 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, GAPDHP34 is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, GAPDHP34 RNA expression shows 6,566 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KICH, THCA, and KIRP as cancer lineages where GAPDHP34 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP34 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP34 survival associations across molecular data types. GAPDHP34 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP34 RNA expression–survival associations across cancer types. High GAPDHP34 expression shows unfavorable associations in KICH, COAD, PCPG, SARC and GBM, but favorable associations in LGG. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify KICH as the clearest survival context for GAPDHP34 RNA expression.
This table summarizes GAPDHP34 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP34. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP34 shows lower tumor expression in THCA, ESCA, LUSC and COAD and higher tumor expression in KIRP and KIRC. The THCA box plot shows higher GAPDHP34 RNA expression in normal versus tumor tissue (log2 FC = −0.039, t-test p < 0.001).
This table shows molecular features associated with GAPDHP34 in patient tissues and cancer cell lines. In patient samples, GAPDHP34 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
